“VISUAL OUTCOMES FOR PATIENTS WITH DIABETIC RETINOPATHY ARE ALWAYS GOING TO BE BETTER IF DIABETIC RETINOPATHY IS IDENTIFIED EARLY.”

- DR. EDWARD CHAUM, M.D., PH.D., VANDERBILT EYE INSTITUTE

An important whitepaper explores how the Welch Allyn RetinaVue care delivery model is shifting the paradigm in diabetic retinopathy care,3 by lowering the cost4 and improving the accessibility5 of diabetic retinopathy exams. Diabetic retinopathy programs, like the RetinaVue care delivery model, enable early detection4 in primary care settings to help close diabetes care gaps,6 increase HEDIS quality scores,6 and reduce healthcare costs.4

Welch Allyn RetinaVue 700 Imager play_circle_outline

In this brief video, learn how the RetinaVue care delivery model could help reduce vision loss from diabetic retinopathy by 95% by enabling early detection and treatment1 - affordably.2


Download to learn about the model that helps preserve vision.7

Please fill out this form to get the important details - and a leading ophthalmologist's perspective - on how the RetinaVue care delivery model can make the early detection of diabetic retinopathy affordable2, improve quality measures6 and close diabetes care gaps.6


Improve HEDIS, STAR and HCC Risk Factors by Closing Care Gaps6

Intercepting patients during routine primary care office visits with a diabetic retinopathy program, such as the RetinaVue care delivery model can help providers achieve up to 90% documented compliance with diabetic retinal exams in just 12 months.6

That means potential financial incentives from quality programs - and more importantly, the opportunity to help save patients' vision.7 Learn more in our eBook, The Solution is in Sight, The Complete Guide to a Successful Diabetic Retinopathy Program.

90%

Diabetic retinopathy programs can achieve up to 90% documented compliance with diabetic retinal exams in just 12 months.6

Welch Allyn® RetinaVue® 700 Imager

Woman Checking RetinaVue700

Help Save Vision for Patients Living with Diabetes7 in Primary Care

Diabetic retinopathy is the leading cause of blindness in working-age adults.8

95%

95% of vision loss due to diabetic retinopathy can be prevented with early detection and treatment.1

RetinaVue Care Delivery Model

Help preserve the vision6 of your patients living with diabetes with a simple eye exam, that takes minutes to complete, for diabetic retinopathy detection during routine primary care visits. Baxter delivers the three keys to a successful diabetic retinopathy program:

Simple and Affordable Hardware

Simple and Affordable2 Hardware

Secure Software Network

Secure Software Network

Nationwide Services and Support

Nationwide Services and Support

Request A Virtual Demo

Request a demo of the RetinaVue care delivery model by completing the form.

Welch Allyn® RetinaVue® 700 Imager
References
  1. New Treatment Options, Better Hope of Preventing Vision Loss from Diabetes | National Eye Institute. https://www.nei.nih.gov/about/news-and-events/news/new-treatment-options-better-hope-preventing-vision-loss-diabetes. Published November 19, 2015. Accessed September 9, 2022.
  2. Cuadros J, Bresnick G. Can commercially available handheld retinal cameras effectively screen diabetic retinopathy? J Diabetes Sci Technol. 2017 Jan; 11(1):135-7. 
  3. Baxter. Early Detection Of Diabetic Retinopathy In Primary Care Settings: A New Model for Preserving Vision in Patients Living with Diabetes. US-FLC147-230075-V2.
  4. Newman, M. (2009) Fiscal Impact of AB 175: Analysis of the Cost Effectiveness of Store and Forward Teleophthalmology, Blue Sky Consulting Group for California Health Care Foundation, www.chcf.org/wp-content/uploads/2017/12/PDF-FiscalImpactAB175AnalysisTeleophthalmology.pdf. 
  5. Liu Y, Swearingen R. Diabetic eye screening: knowledge and perspectives from providers and patients. Curr Diab Rep. 2017 Aug 31; 17(10):94.
  6. Mansberger SL, Gleitsmann K, Gardiner S, et al. Comparing the effectiveness of telemedicine and traditional surveillance in providing diabetic retinopathy screening examinations: A randomized controlled trial. Telemed J E Health. 2013 Dec; 19(12): 942-8.
  7. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12:346-354.
  8. Centers for Disease Control and Prevention. Vision Health Initiative (VHI). https://www.cdc.gov/visionhealth/basics/ced/ Published September 29, 2015. Updated June 3, 2020. Accessed September 9, 2022.
    Rx Only: For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.
 
    Baxter, Hillrom, RetinaVue and Welch Allyn are trademarks of Baxter International Inc. or its subsidiaries.
    HEDIS is a trademark of the National Committee for Quality Assurance (NCQA).
    US-FLC147-240119 (v1.0) 07/2024